• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Barriers to VMS Treatment and Impact on Long-Term Health

Opinion
Video

Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.

Video content above is prompted by the following:

  1. What underlying factors do you think contribute to the persistent under-treatment of VMS in menopausal women, despite the high prevalence of these symptoms?
  2. What factors contribute to patient resistance to conventional VMS treatment options, specifically hormone replacement therapies and nonhormonal therapies such as SSRIs [selective serotonin reuptake inhibitors] and gabapentin?
  3. How do untreated VMS impact the overall quality of life and long-term health outcomes for women, such as risk for cardiovascular disease and Alzheimer’s disease?
Related Videos
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.